The MedTech Innovator isn’t just an accelerator—it’s a launchpad for MedTech startups looking to make a global impact. Since 2013, over 12,500 companies have applied, with 717 graduates transforming healthcare around the world. Our alumni have raised USD 9 billion in funding, achieved 351 FDA approvals, and launched 350 products into the market, all without giving up equity. If you're a startup ready to scale, apply to our program today–https://lnkd.in/g3MYdc9z #Innovation #Healthcare #MedTech #MTIAPAC #MTIAPACALUMNI
MedTech Innovator Asia Pacific’s Post
More Relevant Posts
-
Yesterday, I had the pleasure of participating in a panel discussion on late-stage investment in the medical device sector. The session, moderated by David Cassak from MedTech Strategist, gave us insights into funding strategies for startups approaching late-stage funding. My key takeaways: → Commercialization is key Securing initial approvals and demonstrating market readiness is crucial for attracting serious late-stage investments, particularly with the focus of M&A activities on commercially viable entities. → Build early investor relationships Engaging early and consistently with potential late-stage investors significantly increases your chances of securing investment when it matters most. → Stay resilient The investment landscape is cyclical and demanding. Startups need to remain resilient and adaptable through fluctuating market conditions. → Focus on clinical needs over technology The primary driver for investment should be the potential to meet unmet clinical needs, not just technological innovation. → Prepare for in-depth evaluations Startups at this stage need to be prepared to show their product's capabilities, solid business models, clear regulatory pathways, and effective commercial strategies. → Engage with the market early Showing early market traction is key. Investors want to see that startups can do both: enter the market and effectively expand their share. These insights are valuable for any med tech startup dealing with the complex waters of late-stage funding. Yes, the path to securing necessary capital at this stage is complex but understanding these principles can significantly enhance a startup’s strategy to scale and succeed. #medtech #investmentstrategies #startupfunding #innovationsummitdublin #medtechinnovator
-
-
Our CEO, Daniel Adler, shared his experience from yesterday's panel on late-stage investment in the medical device sector. Moderated by David Cassak, editor in chief at the MedTech Strategist, the discussion featured insights from top industry leaders like Susana Amorim Lopes from Gilde Healthcare, Olivier Litzka from Andera Partners, Ruben Osnabrugge from 415 Capital, and Alexander Schmitz from Endeavour Vision. The discussion shed light on essential strategies for startups dealing with the complexities of funding as they scale. These insights, while highlighting the challenges faced by startups at the late investment stage, also provide a roadmap that can significantly improve a startup’s ability to scale and succeed. #medtech #investmentstrategies #startupfunding #healthcareinnovation
Yesterday, I had the pleasure of participating in a panel discussion on late-stage investment in the medical device sector. The session, moderated by David Cassak from MedTech Strategist, gave us insights into funding strategies for startups approaching late-stage funding. My key takeaways: → Commercialization is key Securing initial approvals and demonstrating market readiness is crucial for attracting serious late-stage investments, particularly with the focus of M&A activities on commercially viable entities. → Build early investor relationships Engaging early and consistently with potential late-stage investors significantly increases your chances of securing investment when it matters most. → Stay resilient The investment landscape is cyclical and demanding. Startups need to remain resilient and adaptable through fluctuating market conditions. → Focus on clinical needs over technology The primary driver for investment should be the potential to meet unmet clinical needs, not just technological innovation. → Prepare for in-depth evaluations Startups at this stage need to be prepared to show their product's capabilities, solid business models, clear regulatory pathways, and effective commercial strategies. → Engage with the market early Showing early market traction is key. Investors want to see that startups can do both: enter the market and effectively expand their share. These insights are valuable for any med tech startup dealing with the complex waters of late-stage funding. Yes, the path to securing necessary capital at this stage is complex but understanding these principles can significantly enhance a startup’s strategy to scale and succeed. #medtech #investmentstrategies #startupfunding #innovationsummitdublin #medtechinnovator
-
-
Valuable insights for any medtech start-up looking for late-stage funding.
Yesterday, I had the pleasure of participating in a panel discussion on late-stage investment in the medical device sector. The session, moderated by David Cassak from MedTech Strategist, gave us insights into funding strategies for startups approaching late-stage funding. My key takeaways: → Commercialization is key Securing initial approvals and demonstrating market readiness is crucial for attracting serious late-stage investments, particularly with the focus of M&A activities on commercially viable entities. → Build early investor relationships Engaging early and consistently with potential late-stage investors significantly increases your chances of securing investment when it matters most. → Stay resilient The investment landscape is cyclical and demanding. Startups need to remain resilient and adaptable through fluctuating market conditions. → Focus on clinical needs over technology The primary driver for investment should be the potential to meet unmet clinical needs, not just technological innovation. → Prepare for in-depth evaluations Startups at this stage need to be prepared to show their product's capabilities, solid business models, clear regulatory pathways, and effective commercial strategies. → Engage with the market early Showing early market traction is key. Investors want to see that startups can do both: enter the market and effectively expand their share. These insights are valuable for any med tech startup dealing with the complex waters of late-stage funding. Yes, the path to securing necessary capital at this stage is complex but understanding these principles can significantly enhance a startup’s strategy to scale and succeed. #medtech #investmentstrategies #startupfunding #innovationsummitdublin #medtechinnovator
-
-
🌟 Only 1 Week Left: Discover Investment Gems in HealthTech! 🌟 We’re just one week away from revealing opportunities that could reshape the healthcare industry! Don’t miss our showcase on April 25th, featuring leading-edge startups from the UK, Sweden, and Israel. Why Consider Strata’s Portfolio? - Proven Success: Over €90M secured for deep-tech startups, driving forward the future of healthcare. - Selective Process: We maintain high standards with less than a 1% acceptance rate to ensure only the most promising ventures make it. - Broad Impact: With a European reach, our startups are poised to make a global impact. Event Highlights: - Targeted Investments: Startups seeking funding between 0.5M-10M EUR, at TRL 5-6. - Sector Focus: Innovations across Medical Devices, Pharma, and E-health. - Networking Opportunity: Connect with founders and industry leaders. 📅 Save the Date: - When: April 25, 2024, 15:00-16:30 CET - Where: Zoom - RSVP here: https://lnkd.in/df2-vCaW 🔗 Last chance to register! Secure your spot and explore a lineup set to revolutionise healthcare. Invest with us and be part of the next big breakthrough in HealthTech. 💡 #HealthTech #InvestmentOpportunity #StartupShowcase #DeepTech #FutureOfHealthcare
-
I help innovative companies fund their growth by leveraging the R&D Tax Incentive. Email me at 𝙗𝙚𝙣@𝙗𝙪𝙡𝙡𝙚𝙩𝙥𝙤𝙞𝙣𝙩.𝙘𝙤𝙢.𝙖𝙪 and I can give you some tips on how to get it. ✅
Ever pondered what sets successful applicants apart in securing up to $50,000 for medtech innovation? The Medtech Market Growth Program isn't just another grant; it's a launchpad for startups ready to make significant healthcare impacts. Discover the insider tips and criteria that could elevate your application from hopeful to funded. Ready to transform your medtech solution's path to the market? Click here: https://bit.ly/3P4heeX
-
-
🔬📅 [Webinar] Medtech companies are at the forefront of innovation for patient health, but they face unique IP challenges that need careful navigation to build a robust strategy in Europe. 🌐 Whether you are an international medtech company looking to protect your IP in Europe or a European medtech startup, this webinar is for you! Join us for an insightful session where we will delve into these critical issues and provide strategies to protect, enforce, and maximize the value of your IP rights in Europe. 🎯 Key Topics: ▪ 360 °view of the IP of your project ▪ Strategies to protect and enforce your rights in Europe ▪ Preparing for the IP due diligence of a medtech start-up 📆 This webinar will be held on two different dates with identical content for your convenience: ▪ Tuesday, July 2, 2024, from 5:00 pm to 6:00 pm CEST ▪ Tuesday, July 16, 2024, from 9:00 am to 10:00 am CEST Do not miss this opportunity to optimize your IP strategy in Europe! To register, follow the link in the comments 👇 #Medtech #IPStrategy #Innovation #Webinar #Startups #HealthcareInnovation #IPProtection #Regimbeau
-
-
Many medtech startups belief their innovation will go sky rocket. Biggest showstopper (besides lack of funding) is the limited willingness to pay (no dedicated reimbursement, no procedure code etc.). An underestimated strategy is partnership with leading medtech players, which might see strong value in the startup’s innovation and can create a complementary offering, which helps them to differentiate and provide more value to the healthcare professional / patient. The attached list shows reasons why leading medtech companies seriously consider partnerships with innovative startups. Reach out if you need help.
-
-
mHUB is currently recruiting for its next MedTech Accelerator cohort. Applications will close on September 12, 2024. The program will commence in Chicago this November. This cohort is supported by strategic industry partners Baxter International Inc., Endeavor Health, and GE Healthcare. The mHUB MedTech Accelerator is a six-month, hands-on startup accelerator focused on the product development and commercialization of early-stage, high-potential hardtech startups. Each cohort supports 8-10 demand-driven, early-stage startups for direct investment, product development and prototyping, mentorship, business modeling, and piloting. The program and its supporting partners are seeking demand-driven, novel medical device technologies in chronic disease management, disease detection, robotic or automated devices, connected therapeutic devices, minimally invasive monitoring, improved drug delivery methods, surgical instruments, and more. Participants will receive a $200K initial investment through mHUB Product Impact Fund - $142.5K cash and $60K in in-kind benefits - on a pre-money SAFE in exchange for 6.5% equity. Learn more or apply here: https://lnkd.in/e8PrYXuC #chicago #illinois #startups #startup #prototype #smallbusiness #business #hardtech #techstartup
-
-
🙋♀️ Do you believe in the promise of #DigitalHealth to improve #patient outcomes and #reducecost in #drugdevelopment? 💊 📲 Do you want to know how to bridge the gap between #pharma and digital #health #startups working on these innovative solutions? 💥 PharmStars knows how to bring startups and #biopharma together to bridge the pharma/startup gap! Our 10-week #accelerator program is designed to prepare startups for more productive engagements with pharma, teaching them what they need to know. 🚀 🌏 PharmStars is a virtual #accelerator, open to digital health startups from around the world because healthcare #innovation has no bounds 🙌 and happens anywhere. Our Fall accelerator will focus on "Digital Innovations in #ClinicalTrials." Learn more and apply (deadline is July 15!) 👉 👉 👉 www.PharmStars.com #transformation #healthcare #biotech #biopharma #entrepreneurs #digitaltransformation #digitalinnovation, #remotemonitoring #patientexperience #clinicaltrials #digital #innovation #digitalhealth #startups #virtualtrials #accelerator #acceleratorprogram #datacollection #RemotePatientMonitoring #RPM #datamanagement
PharmStars
pharmstars.com
-
CEO and Board Member Med Tech and Dental / Expert in Corporate & Entrepreneurial PE ventures. Specialist in Patient-Centric Medical and Dental Solutions / Expert in Operations, Distribution & Product development
2024 is set to be a pivotal year for digital health startups. I sit on two startup boards (one in medtech and one in dental software) and both are doing amazing things that will advance their respective areas. They is still money available and interested buyers both strategic and sponsor! Subscribe to Medtech Strategist for a solid breakdown of the landscape and expert insight. #Medtech #MedicalDevices #DigitalHealth
Now Available: Digital Edition of MedTech Strategist March 2024. Funding for digital health start-ups crashed after peaking during the pandemic. For companies founded in those frothier times, 2024 could be the year of reckoning. Also inside: key takeaways from AAOS 2024; part 2 of our deep dive into the venous device market; and a look at promising neurostimulation companies in MedTech Innovator's accelerator program. Plus profiles of Miread Medical, NeuraSignal, and Synchrony Medical. View here: https://bit.ly/43Akg0z #medicaldevices #medtech #digitalhealth #startups #digitaledition #MedTechStrategist
-
